Funding momentum Vast Therapeutics has secured multiple NIH grants totaling nearly $4 million across 2024–2025 and has ongoing government support for inhaled nitric oxide programs, signaling potential for funded collaborations, co-development, or contract research opportunities aligned with respiratory infectious disease targets.

Clinical progress With Phase 1 data for inhaled ALX1 presented at ATS 2026 and a clear path toward clinical development, there is an opening for partnering on late preclinical to early clinical programs, including potential license or strategic alliance discussions to accelerate go-to-market timelines.

Competitive positioning ALX1 is positioned as a nitric oxide–based antimicrobial alternative with reduced risk of traditional resistance mechanisms, suggesting sales opportunities to unmet needs in chronic lung infections such as Pseudomonas aeruginosa and Mycobacterium abscessus within hospital and specialty care settings.

Strategic partnerships Recent recognition as a Qualified Infectious Disease Product and ongoing preclinical-to-clinical development indicate a receptive environment for collaborations with larger biopharma, contract development and manufacturing organizations, or academic partnerships to de-risk and scale inhaled NO platforms.

Market expansion The combination of an inhalation formulation capability, a focused respiratory disease portfolio, and a growing clinical pipeline creates upsell opportunities to specialty distributors, respiratory clinics, and PI-led clinical trial networks seeking innovative therapies for chronic infections and inflammation.